Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1990-8-13
|
| pubmed:abstractText |
Fourteen patients with T-cell-derived leukemia and lymphoma underwent high-dose chemoradiotherapy and anti-T-cell monoclonal antibody-treated autologous bone marrow transplantation (ABMT). All patients were either in sensitive relapse or had adverse prognostic features, and five patients had a history of bone marrow involvement with disease. Patients received a median of 2 (1 to 3) prior chemotherapy regimens; 10 patients received local radiotherapy. After high-dose ablative therapy, greater than 500/mm3 granulocytes and greater than 20,000 untransfused platelets/mm3 were noted at a median of 23 (13 to 48) and 26 (15 to 43) days post-ABMT, respectively. Natural killer (NK) cells, T cells (predominantly T8+), and monocytes were noted within the first 1 to 2 months post-AMBT, as seen in other series. Disease-free survival was a median of 10.1 months, 5.9 months for patients with T acute lymphoblastic leukemia or lymphoblastic lymphoma and 25.6 months for patients with T non-Hodgkin's lymphoma (NHL). Toxicities were common and severe. Thirty-six percent of patients developed bacteremias early post-BMT. Late complications included a skin rash consistent with graft versus host disease; infections with Herpes zoster, hepatitis, and Pneumocystis carinii; and the development of Epstein-Barr virus associated lymphoproliferative syndrome. Our findings suggest that patients who have undergone T-depleted ABMT have a profound immunodeficiency not reflected in the phenotypic reconstitution of the T and NK cells. Characterization of the functional deficiency may facilitate the development of methods to reduce the long-term toxicity of AMBT in these patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
76
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
235-44
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2194591-Adult,
pubmed-meshheading:2194591-Aged,
pubmed-meshheading:2194591-Bone Marrow Transplantation,
pubmed-meshheading:2194591-Cyclophosphamide,
pubmed-meshheading:2194591-Female,
pubmed-meshheading:2194591-Graft vs Host Disease,
pubmed-meshheading:2194591-Hepatitis,
pubmed-meshheading:2194591-Herpes Zoster,
pubmed-meshheading:2194591-Humans,
pubmed-meshheading:2194591-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:2194591-Lymphoma, Non-Hodgkin,
pubmed-meshheading:2194591-Lymphoproliferative Disorders,
pubmed-meshheading:2194591-Male,
pubmed-meshheading:2194591-Middle Aged,
pubmed-meshheading:2194591-Phenotype,
pubmed-meshheading:2194591-Pneumonia, Pneumocystis,
pubmed-meshheading:2194591-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:2194591-Transplantation, Autologous
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications.
|
| pubmed:affiliation |
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115.
|
| pubmed:publicationType |
Journal Article
|